— Why it moved
Why VTGN Stock Spiked and Faded Today — September 23, 2026
VistaGen released trial extension data for its anxiety nasal spray, but early momentum evaporated into a deep red close.
What moved VTGN stock
VistaGen Therapeutics is a clinical biopharma firm focused on central nervous system disorders. The company released positive preliminary safety data from a Phase 3 extension trial for its social anxiety nasal spray after hours on Tuesday. Skepticism mounted early Wednesday after analyst coverage noted the company likely still needs two additional pivotal trials before seeking FDA approval.
The mechanics
With an $11.16 million market cap and a float of 41.4 million shares, the stock gapped up 53.58% at the session's start. Day traders turned over more than 574 million shares, churning the float nearly fourteen times over before the volume died.
VTGN by the numbers
The alert window
The alert pinged at $0.4753 at 10:02 AM. Anyone following had to sit through a quick drop to $0.4559 before the price touched $0.5476 at 10:04 AM, delivering a 15.2% top. You had a tiny two-minute window to hit the peak, and the price stayed above the alert level for only 10 minutes total.
How VTGN's move ended
The stock collapsed through the morning and closed at $0.3649, down 23.2% from the alert price. That is standard behavior for low-cash biotechs facing years of additional trial expenses.
The tell: Trial extension data without a clear path to regulatory filing is usually just liquidity for upcoming dilution.